• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Use of probiotics in the increase of male fertility. The present invention relates to the use of lactobacillus rhamnosus in combination with bifidobacterium longum in the preparation of a composition for increasing male fertility in a subject. In particular, said strains are strains of lactobacillus rhamnosus cect 8361 and bifidobacterium longum cect 7347. Likewise, the composition comprising said strains lactobacillus rhamnosus cect 8361 and bifidobacterium longum cect 7347 is also described. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2575828A1
    申请号:ES201431977
    申请日:2014-12-31
    公开日:2016-07-01
    发明作者:Vanesa Robles Rodríguez；David GARCÍA VALCARCE；Daniel RAMÓN VIDAL；Salvador GENOVÉS MARTÍNEZ；Patricia Martorell Guerola；Mª Empar CHENOLL CUADROS
    申请人:Biopolis SL；Universidad de Leon；
    IPC主号:
    专利说明:

    5
    10
    fifteen
    twenty
    25
    30
    35
    Use of probiotics in increasing male fertility
    DESCRIPTION
    The present invention relates to the use of a composition comprising two strains of the microbial species Lactobacillus rhamnosus and Bifidobacterium longum with probiotic capacity to increase male fertility. Therefore, the present invention is encompassed within the field of human and animal reproduction, with applications in both the pharmaceutical and agri-food sector.
    STATE OF THE TECHNIQUE
    Probiotics are live microorganisms that when ingested in an appropriate dose confer a health benefit to the consumer. Basically they have been used as ingredients in functional foods or nutritional supplements, so they have been and are of great interest to the agri-food and pharmaceutical industries, respectively. The vast majority of probiotics used to date are usually effective at the level of the digestive tract and positively influence digestive pathologies such as colitis, constipation or intestinal inflammation, among others. However, there are isolated cases in the scientific literature that refer to the use of probiotics in vaginal infections, in skin problems or even in obesity or in autism.
    The use of probiotics in the field of human reproduction is limited and focuses mainly on the female factor and the previously described cases of vaginal infections. In this sense, there are studies in which probiotics have been used as therapy in bacterial vaginosis, providing positive results in some clinical studies (Mastromarino et al., 2013. New Microbiol. 36 (3): 229-38; Borges et al. , 2014. Arch Gynecol Obstet., 289 (3): 479-89). On the contrary, the effect of probiotics on male fertility in humans has not been described. In the animal model of the zebrafish it has been found that the intake of probiotics significantly increases molecular markers associated with reproductive quality (Riesco et al., 2013. Evaluation of a probiotic diet on zebrafish sperm quality markers. 4th International workchop on the biology of Fish Gametes (Albufeira, Portugal)), but to date there is no scientific publication that evaluates the effect of probiotic intake on sperm quality parameters
    5
    10
    fifteen
    twenty
    25
    30
    35
    in humans, or that correlates the intake of these supplements with improvements in sperm mobility.
    On the other hand, the antioxidant effect of lactic bacteria and bifidobacteria has been studied but never in relation to sperm quality in humans although in animals (Riesco et al., 2013 cited ad supra). During the last decades, clinical studies have been developed to establish the beneficial effects of antioxidant treatments in improving sperm parameters in men, as well as in the rates of fertilization or pregnancy in their partners. The most commonly studied antioxidants have been vitamin C, vitamin E, selenium, glutathione, zinc, N-acetyl-cystem and L-carnitine (Gharagozloo et al., 2011. Hum Reprod. 26 (7) : 1628-40; Ko and Sabanegh, 2012. J Androl 33 (3): 292-308; Showell et al., 2013. Cochrane Database Syst Rev, 5; 8: CD007807). Some of these studies evaluate the effect of these antioxidants in in vitro assays (added as supplements in the cryoprotectant solution) and conclude that there is a beneficial effect of these additives in the protection of sperm against oxidative molecules generated during freezing protocols. - defrosting (Walczak-Jedrzejowska et al., 2013. Cent European J Urol. 66 (1): 607). Other studies evaluate the effect of oral antioxidant administration on sperm parameters. For example, in 2010, Ross et al. (Ross et al., 2010, Reprod Biomed Online, 20 (6): 711-23) reviewed the beneficial effects of oral antioxidant intake on sperm parameters. The Spanish patent ES2225625 describes a composition to improve the quality of human sperm comprising at least one source of zinc and, optionally, vitamin B12, magnesium, betama, choline, SAM, vitamin B2 and vitamin B6. Similarly, the Spanish patent ES2397657 describes a combination preparation to improve the sperm quality of an individual, comprising, as active substances, L-carnitine, coenzyme Q, vitamin E, a source of zinc, vitamin B, a source of selenium, glutathione, L-arginine or salts or derivatives thereof. However, the effects of these treatments do not always last over time and it is not known whether they reduce sperm DNA fragmentation; one of the most relevant parameters in sperm quality.
    Therefore, there is a need in the state of the art for providing alternative methods to increase male fertility, improving sperm quality, which do not present the aforementioned drawbacks.
    5
    10
    fifteen
    twenty
    25
    30
    35
    DESCRIPTION OF THE INVENTION
    The inventors of the present invention have discovered that the combined administration of a strain of Lactobacillus rhamnosus and a strain of Bifidobacterium longum provides an increase in male fertility. In a particular embodiment, the strains are Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347. As shown in Example 1, the intake by the study subjects of a composition comprising the combination of a Lactobacillus rhamnosus strain and a strain of Bifidobacterium longum produced an increase in sperm motility and a reduction in sperm DNA fragmentation; Two key parameters in the evaluation of semen quality. Thus, the intake of these strains in a probiotic combination improves seminal quality and, therefore, increases male fertility. In addition, this increase in fertility is maintained even six weeks after the last intake has ended, thereby achieving a long-term effect. One possible explanation for these results would be that the combination of the antioxidant capacity of the Lactobacillus rhamnosus CECT 8361 strain with the anti-inflammatory capacity of the Bifidobacterium longum CECT 7347 strain is responsible for this increase in sperm motility and the reduction of fragmentation of the Sperm DNA Therefore, the invention described herein allows the use of bacterial strains with probiotic properties to address therapies in order to increase male fertility before performing an assisted reproduction or natural reproduction technique or even before making sperm donations for future insemination.
    Based on this discovery, a series of inventive aspects have been developed that will be described in detail below.
    Use of the combined administration of the Lactobacillus rhamnosus and Bifidobacterium longum species strains to increase a subject's male fertility.
    The inventors of the present invention have discovered that the combined administration of a strain of Lactobacillus rhamnosus and a strain of Bifidobacterium longum provides an increase in male fertility. However, due to the extraordinary antioxidant capacity of Lactobacillus rhamnosus, in particular, L.
    5
    10
    fifteen
    twenty
    25
    30
    35
    rhamnosus CECT 8361, in comparison with other Lactobacillus species, the possibility of using Lactobacillus rhamnosus individually in the development of a pharmaceutical composition to increase male fertility cannot be ruled out. The authors of the present invention think that the antioxidant capacity of Lactobacillus rhamnosus, in particular the strain L. rhamnosus CECT 8361, protects sperm from reactive oxygen species that can alter sperm membranes, DNA integrity and sperm motility Therefore, the inventors think that the antioxidant capacity of the strain increases the seminal quality; in particular, it increases sperm motility and decreases sperm DNA fragmentation, which ultimately increases male fertility. On the other hand, due to the anti-inflammatory capacity of Bifidobacterium longum, in particular, the strain Bifidobacterium longum CECT 7347, the present invention also contemplates the possibility of using Bifidobacterium longum, in particular Bifidobacterium longum CECT 7347, individually to increase the male fertility The authors of the present invention think that the ability of Bifidobacterium longum CECT 7347 to reduce levels of the inflammatory factor TNF-a and increase the production of the anti-inflammatory cytokine IL-10 protects sperm from oxidative stress. Therefore, compositions comprising at least L. rhamnosus CECT 8361 or Bifidobacterium longum CECT 7347 and their use in increasing the male fertility of a subject are also contemplated in the present invention.
    In one aspect, the invention relates to the use of Lactobacillus rhamnosus in combination with Bifidobacterium longum in the preparation of a composition (hereinafter, "composition of the invention") to increase male fertility in a subject.
    Lactobacillus rhamnosus is a bacterium commonly used as a probiotic, found mostly in yogurt and other dairy products. The scientific classification of Lactobacillus rhamnosus is: Kingdom: Bacteria, Division: Firmicutes, Class: Bacilli, Order: Lactobacillales, Family: Lactobacillaceae, Genus: Lactobacillus, Species: Lactobacillus rhamnosus. On the other hand, Bifidobacterium longum is a gram-negative, catalase-negative, rounded bacterium found in the gastrointestinal tract where it produces lactic acid. The scientific classification of Bifidobacterium longum is: Kingdom: Bacteria, Division: Firmicutes, Class:
    5
    10
    fifteen
    twenty
    25
    30
    35
    Actinobacteria, Order: Bifidobacteriales, Family: Bifidobacteriaceae, Genus: Bifidobacterium, Species: Bifidobacterium longum.
    In the present invention it is understood to "increase male fertility" in a subject improve the semen quality of said subject, which entails increasing the chances of fertilizing a female and obtaining offspring. As understood by the person skilled in the art, in the In the context of the present invention, the semen quality of a subject is improved with respect to the semen quality of said subject before ingesting the strains of the invention.The seminal quality of a subject can be measured by a multitude of parameters such as, but not limited to sperm motility, sperm viability, morphology, sperm membrane composition, sperm concentration, ejaculate volume and sperm DNA integrity There are several methods described in the state of the technique to measure all these parameters and their use is routine practice for the person skilled in the art. Some evaluate the integrity of the DNA sperm: the TUNEL test (Terminal Transferase dUTP Nick End Labeling), the sperm chromatic structure analysis (SCSA) test, the comet test, and the sperm chromatin dispersion test (SCD). Other tests identify defects in the sperm chromatin packaging: toluidine blue staining, with acridine orange and cromomycin A. In addition, there are various molecular markers such as different types of RNA (mRNA, microRNAs, etc.) that can be associated with a higher seminal quality despite not being performed routinely in weather.
    Therefore, in a particular embodiment, the increase in male fertility comprises the increase in sperm motility, sperm viability, sperm membrane composition, morphologically normal sperm concentration and / or number Total sperm in the ejaculate, and / or includes the decrease in sperm DNA fragmentation and the improvement of sperm chromatin integrity.
    A decrease in sperm DNA fragmentation prevents loss of motility, fertility and decreases the likelihood of alterations during early embryonic development and in the progeny.
    5
    10
    fifteen
    twenty
    25
    30
    35
    In the present invention it is understood that the integrity of the sperm chromatin is improved when the sperm DNA is organized in a compact and stable manner, achieving a packaging of the genetic material that ensures that the DNA is delivered in such a physical and chemical form, which is capable of decondensing at the appropriate moment of the fertilization process and transmitting the DNA without defects.
    In the present invention the term "subject" is equivalent to the term "individual"; therefore both terms can be used interchangeably in the present invention. "Subject" means, in addition to any individual, any male animal belonging to any species that produces gametes to reproduce. Examples of subjects include, but are not limited to, animals of commercial interest such as fish (trout, sardines, carp, salmon, etc.), birds (chickens, ostriches, chickens, geese, partridges, etc.), rabbits, hares, animals domestic (dogs, cats, etc.), sheep, goats (goats, etc.), pigs (wild boars, pigs, etc.), equine cattle (horses, ponies, etc.), cattle or cattle (bulls , oxen, etc.); animals of cinematic interest, such as deer, deer, reindeer, etc .; animals of ecological interest, that is, animals that are in danger of extinction or whose populations in nature are scarce such as, for example, white tigers, rhinos, pandas, pumas, lynx, etc .; and human beings. However, in a particular embodiment, the subject is a fish or a mammal, preferably, a mammal selected from the group consisting of a human being, a pig, a horse, a rabbit, an ox and a bull.
    The use described in the present invention can be applied to any male subject to increase their fertility, regardless of whether the fertility is diminished (subfertile) or not (fertile). In male fertile subjects, the increase in fertility may be interesting to increase reproductive capacity. On the other hand, the increase in fertility can also be interesting because it represents, in general, an advantage for human couples who wish to have greater chances of pregnancy. In subfertile male individuals, the composition of the invention can be used to treat said subfertility, that is, to improve the chances of successful fertilization.
    In another advantageous application, the composition of the invention can be administered to a male individual of a species of mammals and, in particular, to a man, without knowing a priori whether said male individual is fertile or subfertile. By way of example, in this
    5
    10
    fifteen
    twenty
    25
    30
    35
    The composition of the invention can be administered to the male individual of a couple when the fecundation takes time to perform, for example, to avoid having to perform tests and / or before performing any test. This is important since the sperm test is expensive and annoying for the individual in question, because the specificity and sensitivity of the test systems vary and because there may be fluctuations in the quantity and / or quality of sperm.
    The composition of the invention can also be used in male individuals of couples who intend to have a child, that is to increase the chances of fertilization and / or to counteract any male fertility problem, again without the need for prior testing. .
    The composition of the invention can also be used to prevent or counteract in the long term the effects of the fluctuation of the quantity and quality of sperm with respect to reproduction.
    On the other hand, the composition can also be used prophylactically to prevent a decrease in sperm quality in at-risk individuals or individuals suffering from urogenital tract dysfunctions, and / or other dysfunctions that may have effects on sperm quality ( for example, in male individuals who are (or should be) undergoing a pharmacological treatment) and during a pharmacological treatment or radiotherapy. In addition, the compositions and / or preparations of the invention can be used, for example, to improve sperm quality that may be affected by factors such as malnutrition, environmental factors, and / or exposure to harmful substances.
    The proportion of the Lactobacillus rhamnosus strain with respect to the Bifidobacterium longum strain may vary over a wide range. The Lactobacillus ratio. rhamnosus: Bifidobacterium longum in the composition of the invention includes, but is not limited to, 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, 50: 50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, 90:10 and 95:05. However, in a particular embodiment, the ratio Lactobacillus rhamnosus: Bifidobacterium longum is,
    approximately 50:50.
    As the person skilled in the art understands, the composition of the invention can be formulated for pharmaceutical administration, that is, being part of others.
    5
    10
    fifteen
    twenty
    25
    30
    35
    Pharmacological products consumed or ingested by the subject, or for their food administration, is dedr, being part of the foods that are consumed in the diet by a subject. Therefore, in a particular embodiment, the composition is a pharmaceutical composition or a functional nutritional composition.
    The pharmaceutical composition is a set of components that is formed, at least, by the strains of the invention in any concentration, which, additionally, may comprise one or more components or compounds that possess some biological, pharmacological and / or veterinary activity; in particular, compounds that when orally administered to a subject can exert said biological activity. These additional compounds may be one or more compounds known per se to be administered (orally) to a male subject or individual of a species, in particular, of a species of mammals, a beneficial influence on fertility. and / or on the sperm quality of a male individual; and / or they can be one or more components that, after administration to a subject, can subsequently increase, reinforce and / or boost the activity of the strains of the invention. As the person skilled in the art understands, the additional compounds must be compatible with the strains of the invention. Thus, in the context of the present invention, the term "pharmaceutical composition" also includes veterinary compositions.
    The additional compound (s) may be one or more compounds that guarantee spermatogenesis or any part and / or process of spermatogenesis. Some non-limiting examples of these compounds include, but are not limited to:
    - Magnesium, that is, in the form of a bioavailable source of magnesium as a bioavailable magnesium salt (for example, magnesium citrate);
    - One or more vitamins and, in particular, vitamin B12 and / or vitamin B2;
    - An appropriate source of methyl groups, such as methionine, betama and / or choline; the latter, for example, in the form of phosphatidylcholine; or an adequate source thereof, such as lecithin;
    - An appropriate methylation agent such as S-adenosyl methionine (SAM);
    - A source of glucose;
    - or any suitable combination thereof.
    5
    10
    fifteen
    twenty
    25
    30
    35
    These additional components may also be one or more compounds that improve glutathione (reduced) levels of sperm. A non-limiting example of this type of compounds is vitamin B6, which may be present or administered in the form of a (stable) pyridoxine or a derivative thereof, such as pyridoxal or pyridoxamine. The improvement of the glutathione status of sperm is important in order to improve sperm quality, including, but not only, increased sperm half-life, its mobility and / or the ability to fertilize an egg. Other components suitable for use in compositions and preparations of the invention may comprise an appropriate source of copper and, in particular, Cu2 + ions, such as copper (II) sulfate, copper (II) carbonate or copper citrate (II).
    Examples of other compounds that help increase male fertility include, but are not limited to, folic acid, zinc, glutathione, arginine and alpha-lipoic acid.
    In a particular embodiment, the pharmaceutical composition comprises a pharmaceutically acceptable carrier and / or excipient.
    The term "excipient" refers to a substance that aids the absorption of any of the components of the composition, that is, of the strains of the invention, or stabilizes said components and / or aids in the preparation of the pharmaceutical composition in the sense of giving it consistency or providing flavors that make it more pleasant. Thus, the excipients could have the function of keeping the components together (for example, starches, sugars or celluloses), of sweetening, of providing a dye, of protecting the active ingredient (for example, to isolate it from the air and / or moisture), to fill a tablet, capsule or any other form of presentation, to disintegrate to facilitate the dissolution of the components, etc., without excluding other types of excipients not mentioned in this paragraph. Therefore, the term "excipient" is defined as that matter which, included in Galenic forms, is added to the active principles or their associations to enable their preparation and stability, modify their organoleptic properties or determine the physico-chemical properties of the Pharmaceutical composition and its bioavailability. The "pharmaceutically acceptable" excipient must allow the activity of the compounds of the pharmaceutical composition, that is, to be compatible with the strains of the invention.
    5
    10
    fifteen
    twenty
    25
    30
    35
    The "galenic form" or "pharmaceutical form" is the provision to which the active ingredients and excipients are adapted to constitute a composition or a drug. It is defined by the combination of the way in which the pharmaceutical composition is presented by the manufacturer and the way in which it is administered.
    The "vehicle" or "carrier" is preferably an inert substance. The function of the vehicle is to facilitate the incorporation of other compounds, allow a better dosage and administration and / or give consistency and form to the pharmaceutical composition. Therefore, the vehicle is a substance that is used in the drug to dilute any of the components of the pharmaceutical composition of the present invention to a certain volume or weight; or that, even without diluting said components, it is capable of allowing a better dosage and administration and / or giving consistency and form to the drug. When the presentation form is liquid, the pharmaceutically acceptable vehicle is the diluent.
    In addition, the excipient and the vehicle must be pharmacologically acceptable, that is, that the excipient and the vehicle are allowed and evaluated so as not to cause damage to the subject to which it is administered.
    In each case the form of presentation of the pharmaceutical composition will be adapted to the type of administration used. Therefore, the composition can be presented in the form of solutions or any other form of administration that is chemically permitted and in a therapeutically effective amount. The pharmaceutical composition of the invention can be formulated in solid, semi-solid or liquid forms, such as tablets, capsules, powders, granules, solutions, suppositories, gels or microspheres. In a particular embodiment, the pharmaceutical composition is presented in a form adapted to oral administration.
    The form adapted to oral administration refers to a physical state that can allow oral administration. Said form adapted to oral administration is selected from the list consisting of, but not limited to, drops, syrup, herbal tea, elixir, suspension, temporary suspension, drinkable vial, tablet, capsule, granulate, seal, pfldora, tablet, tablet , trocisco and lyophilized.
    In addition to that described in previous paragraphs, the present invention also contemplates the possibility that the composition of the invention can be
    5
    10
    fifteen
    twenty
    25
    30
    35
    administer to a subject jointly with other compounds, although these are not part of the composition of the invention. Examples of said compounds have been mentioned in previous paragraphs.
    Thus, administration to the subject of said compounds can be carried out simultaneously or sequentially to the composition of the invention.
    In the event that the composition of the invention is formulated as a functional nutritional composition, said nutritional composition may be a food or be incorporated into a food or food product intended for both human and animal feed. Thus, in a particular embodiment, the functional nutritional composition is selected from a food (which can be a food for specific nutritional purposes or a medicinal food or a functional food) or a nutritional supplement.
    The term "functional nutritional composition" or "functional nutritional composition" of the present invention refers to that food that, regardless of providing nutrients to the subject who takes it, beneficially affects one or more functions of the organism, so that it provides a Better health and well-being. In the present invention, said functional nutritional composition is intended to increase male fertility.
    The term "supplement", synonymous with any of the terms "dietary supplement", "nutritional supplement", "food supplement" or "food supplement", is a component or components intended to supplement the diet. Some examples of dietary supplements include, but are not limited to, vitamins, minerals, botanicals, amino acids and food components, such as enzymes and glandular extracts. They are not presented as substitutes for a conventional food or as single components of a food or a dietary diet, but as a complement to the diet.
    Examples of foods that may comprise a strain of Lactobacillus rhamnosus and a strain of Bifidobacterium longum, or the composition comprising them as explained in previous paragraphs include, but is not limited to, feed, dairy products, plant products, meat products, snacks, chocolates, drinks, baby food, cereals, fried foods, industrial pastries, cookies, etc. Examples
    5
    10
    fifteen
    twenty
    25
    30
    35
    Dairy products include, but are not limited to, products derived from fermented milk (for example, but not limited to, yogurt or cheese) or unfermented (for example, but not limited to, ice cream, butter, margarine or whey). The vegetable product is, for example, but not limited to, a cereal in any form of presentation, fermented or unfermented, or a snack. The drink can be, but not limited to, unfermented milk. However, in a particular embodiment, the food product is selected from the group consisting of a dairy product, a meat product, a vegetable product, a fodder and a beverage.
    In another particular embodiment, the composition of the invention is administered to a subject through the diet.
    As the person skilled in the art understands, Lactobacillus microorganisms. rhamnosus and Bifidobacterium longum have to be present in the composition of the invention in a therapeutically effective amount so that they can exert their effect of increasing male fertility when administered to a subject. In the present invention, "therapeutically effective amount" means that amount of the component of the pharmaceutical composition which, when administered to a subject, is sufficient to produce the effect. Said component of the pharmaceutical composition refers to the strains of the invention. The therapeutically effective amount will vary depending on, for example, the age, body weight, general state of health, sex and diet of the subject, as well as depending on the mode and time of administration, speed. of excretion or the combination of drugs among others, so, in a particular embodiment, the total concentration of microorganisms of the Lactobacillus rhamnosus and Bifidobacterium longum strains in the composition is between 106 and 1012 cfu, preferably 109 cfu. In another embodiment in particular, the administration dose of Lactobacillus rhamnosus and Bifidobacterium longum microorganisms in the composition is between 106 and 1012 cfu / day, preferably, 109 cfu / day, and in another still more particular embodiment, the administration regime is at least once a day, in particular, twice a day, and more in particular, three times a day, once with each meal intake (breakfast, lunch and dinner).
    In a particular embodiment, the Lactobacillus rhamnosus strain is the Lactobacillus rhamnosus CECT 8361 strain, or a strain derived therefrom, and / or the Bifidobacterium longum strain is the Bifidobacterium longum CECT 7347 strain, or a
    5
    10
    fifteen
    twenty
    25
    30
    35
    strain derived from it. This particular embodiment of the invention will be described in detail below.
    Composition II of the invention
    In another aspect, the present invention relates to a composition, hereinafter, "composition II of the invention", comprising Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347, or strains derived therefrom, the combination of which has the capacity of increasing male fertility.
    The Lactobacillus rhamnosus CECT 8361 strain was isolated from the feces of a child less than three months old, healthy and breastfed. This strain was deposited on May 27, 2013 under the Budapest Treaty in the Spanish Collection of Type Crops as an International Deposit Authority (Building 3 CUE, Parc Scientific University of Valencia, Professor Agustm Escardino, 9, 46980 Paterna (Valencia) SPAIN ). The assigned deposit number was CECT 8361 (hereafter “strain of the invention CECT 8361” or “Lactobacillus rhamnosus CECT 8361”). The scientific classification of the strain of the invention CECT 8361 is: Kingdom: Bacteria, Division: Firmicutes, Class: Bacilli, Order: Lactobacillales, Family: Lactobacillaceae, Genus: Lactobacillus, Species: Lactobacillus rhamnosus. During the isolation of the strain of the invention CECT 8361, the inventors observed that Lactobacillus rhamnosus CECT 8361 has, surprisingly, a greater antioxidant activity than other isolates of the genus Lactobacillus, that is, it offers greater protection against oxidative stress to the cells. Thus, in a particular embodiment, the Lactobacillus rhamnosus CECT 8361 strain exhibits a higher antioxidant activity than other Lactobacillus strains. Therefore, the inventors think that the antioxidant capacity of the strain is relevant to explain the increase in semen quality, in particular, in the increase in sperm motility and in the decrease in sperm DNA fragmentation; which, ultimately, increases male fertility.
    The strain Bifidobacterium longum CECT 7347 was isolated from the feces of a healthy child under three months of age subjected to breastfeeding and deposited on December 20, 2007 under the Budapest Treaty at the Spanish Type Culture Collection as an International Authority Deposit (based in Burjassot, Valencia). The deposit number assigned was CECT 7347 (hereafter “strain
    5
    10
    fifteen
    twenty
    25
    30
    35
    of the invention CECT 7347 "or" Bifidobacterium longum CECT 7347 "). The scientific classification of the strain of the invention CECT 7347 is: Kingdom: Bacteria, Division: Firmicutes, Class: Actinobacteria, Order: Bifidobacteriales, Family:
    Bifidobacteriaceae, Generates: Bifidobacterium, Species: Bifidobacterium longum. The strain of the invention CECT 7347 exhibits anti-inflammatory activity.
    Within the present invention, those microorganisms or bacteria that derive from the strain of the invention CECT 8361 and the strain of the invention CECT 7347 are also contemplated and that retain the ability to increase male fertility because they improve semen quality and / or decrease sperm DNA fragmentation and improve chromatin integrity. Examples of strains or microorganisms derived from the inventive strains may be mutants that have variations in their genome with respect to the genome of the strains of the invention but that do not affect the ability of the strains to increase male fertility. Thus, mutant strains derived from the strains of the invention that retain the ability to increase fertility are also contemplated within the present invention. Therefore, in another aspect, the present invention relates to strains derived from the strain of the invention CECT 8361 and from the strain of the invention CECT 7347, with the ability to increase male fertility when administered in combination to a subject .
    The strains derived from the strain of the invention CECT 8361 and the strain of the invention CECT 7347 can be produced naturally or intentionally, by methods of mutagenesis known in the state of the art, for example, but not limited a, the growth of the original strain in the presence of mutagenic or stress-causing agents or by genetic engineering aimed at the modification, deletion and / or inclusion of specific genes. Thus, within the present invention also contemplated genetically modified organisms derived from the strains of the invention that retain their ability to increase male fertility.
    On the other hand, within the present invention, cellular components, metabolites and molecules secreted by the strain of the invention CECT 8361 and by the strain of the invention CECT 7347 or by the strains derived from the strain of the strain of the invention are also contemplated. invention CECT 8361 and the strain of the invention CECT 7347, as well as the compositions comprising said components and the uses
    5
    10
    fifteen
    twenty
    25
    30
    35
    of them to increase male fertility. Among the cellular components of the bacterium could be included the components of the cell wall (such as, but not limited to, peptidoglycan), nucleic acids, membrane components or others, such as proteins, carbohydrates and hydrates. carbon and its combinations (such as lipoprotems, glycolipids or glycoprotems). The metabolites include any molecule produced or modified by the bacteria as a result of its metabolic activity, during its growth, its use in technological processes or during product storage. Examples of these metabolites are, but are not limited to, organic and inorganic acids, proteins, peptides, amino acids, enzymes, Kpids, carbohydrates, lipoprotems, glycolipids, glycoprotems, vitamins, salts, metals or nucleic acids. Secreted molecules include any molecule secreted or released to the outside by the bacteria during its growth, its use in technological processes (for example, food or drug processing) or storage of the product. Examples of these molecules are, but are not limited to, organic and inorganic acids, proteins, peptides, amino acids, enzymes, lipids, carbohydrates, lipoprotems, glycolipids, glycoprotems, vitamins, salts, metals or nucleic acids.
    In the present invention it is understood that a strain or the combination thereof, has the ability to "increase male fertility" when, after ingestion by a subject, said strain / s is / are capable of increasing the quality of the semen of said subject and, with it, of increasing the chances of fertilizing a female and obtaining offspring.
    The proportion of the strain of the invention CECT 8361 and the strain of the invention CECT 7347 in the composition of the invention may vary over a wide range. The ratio Lactobacillus rhamnosus CECT 8361: Bifidobacterium longum CECT 7347 in the composition of the invention includes, but is not limited to, 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40: 60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, 90:10 and 95:05. However, in a particular embodiment the ratio Lactobacillus rhamnosus CECT 8361: Bifidobacterium longum CECT 7347 is approximately 50:50.
    As explained above for the use of the composition of the invention for increasing male fertility, composition II of the invention can go
    5
    10
    fifteen
    twenty
    25
    30
    35
    formulated for pharmaceutical administration or for food administration, Therefore, in a particular embodiment, the composition is a pharmaceutical composition or a functional nutritional composition.
    The pharmaceutical composition is a set of components that is formed, at least, by the strain of the invention CECT 8361 and the strain of the invention CECT 7347, in any concentration, which, additionally, can comprise one or more components or compounds possessing some biological, pharmacological and / or veterinary activity; in particular, compounds that when orally administered to a subject can exert said biological activity. These additional compounds may be one or more compounds known per se that, when administered (orally) to a male subject or individual of a species - in particular, a mammalian species -, a beneficial influence on fertility and / or on the sperm quality of a male individual and / or can be one or more components that, after administration to a subject, can subsequently increase, reinforce, and / or boost the activity of the strain of the invention CECT 8361 and the strain of the invention CECT 7347. As understood by the person skilled in the art, the additional compounds must be compatible with the strains of the invention. Thus, in the context of the present invention, the term "pharmaceutical composition" also includes veterinary compositions.
    The additional compound (s) may be one or more compounds that guarantee spermatogenesis or any part and / or process of spermatogenesis. Some non-limiting examples of these compounds have been described for the preceding inventive aspect and are applicable to composition II of the invention.
    In a particular embodiment, the pharmaceutical composition comprises a pharmaceutically acceptable carrier and / or excipient. The terms "vehicle" and "pharmaceutically acceptable" excipient "have been previously defined in the present description and are applicable to the present inventive aspect.
    In each case, the presentation form of the pharmaceutical composition will be adapted to the type of administration used. The pharmaceutical composition can be formulated in solid, semi-solid or liquid forms, such as tablets, capsules, powders, granules, solutions, gels or microspheres. In a particular embodiment, the
    5
    10
    fifteen
    twenty
    25
    30
    35
    Pharmaceutical composition is presented in a form adapted to oral administration. Examples of oral administration have been previously explained.
    Additionally, the present invention also contemplates the possibility that the composition of the invention can be administered to a subject in conjunction with other compounds. Examples of said compounds have also been cited previously. Thus, administration to the subject of said compounds can be carried out simultaneously or sequentially to the composition of the invention.
    In the event that the composition comprising the strain of the invention CECT 8361 and the strain of the invention CECT 7347 is formulated as a functional nutritional composition, said nutritional composition may be a food or be incorporated into a food / foodstuff intended for both to human feeding as to animal feeding. Thus, in a particular embodiment, the functional nutritional composition is selected from a food (which can be a food for specific nutritional purposes or a medicinal food) or a nutritional supplement. The terms "functional nutritional composition", "supplement" and examples of foods that may comprise the strains of the invention or composition II of the invention, have been described in previous paragraphs. However, in a particular embodiment, the food product is selected from the group consisting of a dairy product, a meat product, a vegetable product, a fodder and a beverage. In another particular embodiment, the composition of the invention is administered to a subject through the diet.
    As the person skilled in the art understands, the strains of the invention have to be present in the composition of the invention in a therapeutically effective amount so that they can exert their effect of increasing male fertility when administered to a subject. The term "therapeutically effective amount" has been previously described, as well as the routes, doses and administration regimens that may be employed in the context of the present invention. In a particular embodiment, the total concentration of Lactobacillus rhamnosus CECT 8361 microorganisms and Bifidobacterium longum CECT 7347 in the composition of the invention is between 106 and 1012 cfu, preferably 109 cfu.
    Method to increase male fertility in a subject
    5
    10
    fifteen
    twenty
    25
    30
    35
    In another aspect, the invention relates to a method for increasing male fertility, hereinafter "method of the invention", which comprises administering to a subject a therapeutically effective amount of a composition comprising Lactobacillus rhamnosus and Bifidobacterium longum, in In particular, the Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347 strains.
    The person skilled in the art will understand that all the particular embodiments described above for the use of Lactobacillus rhamnosus and Bifidobacterium longum are applicable to the method of the invention: forms of administration, forms of presentation, types of composition, doses, subjects that can be treated, etc.
    Throughout the description and claims the word "comprises" and its variants are not intended to exclude other technical characteristics, additives, components or steps. For those skilled in the art, other objects, advantages and characteristics of the invention will be derived partly from the description and partly from the practice of the invention. The following examples and figures are provided by way of illustration and are not intended to be limiting of the present invention.
    BRIEF DESCRIPTION OF THE FIGURES
    Figure 1 is a bar graph describing the variation of motile sperm (%) along the experimental design: C (control; n = 9), T1 (treatment 1; n = 8), T2 (treatment 2; n = 7), L1 (wash 1; n = 8), L2 (wash 2; n = 7). The values (mean ± error) with asterisk are significantly different from the control after performing a Student t-test for related samples (p <0.05).
    Figure 2 is a bar graph describing the variation in the sperm DNA fragmentation index (DFI) throughout the experimental design: C (control; n = 9), T1 (treatment 1; n = 9 ), T2 (treatment 2; n = 7), L1 (wash 1; n = 8), L2 (wash 2; n = 6). The values (mean ± error) with asterisk are significantly different from the control after performing a Student t-test for related samples (p <0.05).
    Figure 3 is a bar graph showing the antioxidant capacity of Lactobacillus rhamnosus CECT 8361 in Caenorhabditis elegans (hereinafter, C. elegans). Scrutiny of twenty-three isolated from the genus Lactobacillus from the collection of
    5
    10
    fifteen
    twenty
    25
    30
    35
    one of the two applicants of the present invention, namely Biopolis, S.L., on the antioxidant activity in C. elegans. The survival percentage of C. elegans fed with each isolate is compared to the survival of C. elegans under control conditions (E. coli OP50). Positive values indicate antioxidant activity and negative values indicate a possible prooxidant effect.
    EXAMPLES
    The invention will be illustrated below by tests carried out by the inventors, which show the effectiveness of the product of the invention.
    Example 1: Improvement of sperm quality after joint administration to a subject of the Lactobacillus rhamnosus CECT 8361 strain and the Bifidobacterium longum CECT 7347 strain
    To address this study, the Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347 strains were selected. This selection was based on the high antioxidant activity of the Lactobacillus rhamnosus CECT 8361 strain and on the anti-inflammatory activity previously described for the Bifidobacterium longum CECT strain 7.
    The administration format was a capsule containing a combination of both microorganisms at fifty percent (50%). The dosage was one capsule per day, corresponding to the administration of 109 cfu / day.
    Under the approval of the Bioethics Committee of the University of Leon, after having signed the corresponding informed consent following the regulations established by the declaration of Helsinki and complying with the legislation in force in the Spanish state, astenozoospermic men who were not under medication and with habits Feeding homogenous participated in the experiment.
    Volunteers donated their ejaculate sample following the instructions in the World Health Organization (WHO, 2010) manual after three days of sexual abstinence and using sterile containers. Donations were collected quickly after sampling to be processed in the laboratory as soon as possible.
    5
    10
    fifteen
    twenty
    25
    30
    35
    The biological samples requested from donors were the following: control, C (prior to the start of probiotic intake); treatment 1, T1 (3 weeks of probiotic intake); treatment 2, T2, (6 weeks of probiotic intake); wash 1, L1 (3 weeks after the end of probiotic intake); and washing 2, L2 (6 weeks after the end of probiotic intake).
    The intake of probiotics was daily. The administration format was one capsule per day containing the two strains Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347 at a concentration of 109 cfu / capsule.
    The sperm was diluted in 1X PBS buffer to a final concentration of 10 to 20 * 106 cells / mL. This dilution was loaded into a Makler counting chamber of 10- ^ m at 37 ° C. The motility of the sperm was evaluated, in the same way in each of the samples, with a computerized sperm analysis system (CASA) consisting of a triocular phase contrast microscope, using a 10 X negative phase contrast lens, equipped with a heating plate at 37 ° C and a Basler A312fc digital camera. The images were captured and analyzed using a computerized motility analyzer with specific settings for human sperm. The system provided the following three parameters globally: (1) percentage of mobile sperm, (2) percentage of progressive sperm and (3) percentage of static sperm.
    The SCSA technique ("Sperm Chromatin Structure Assay") (Evenson) was performed to evaluate DNA fragmentation. Metachromatic staining with acridine orange (AO) was performed with an aliquot of the sample. This molecule emits fluorescence in the red band when combined with denatured DNA and in the green band when combined with a double helix of DNA in good condition.The ejaculates were diluted with TNE buffer (0.15 M NaCl, 0.01 M Tris-HCl, 1 mM EDTA; pH 7.4) at a final cell concentration of approximately 1-2 x 106 cells / mL The samples were immediately frozen in liquid nitrogen until processing, subsequently, the samples were thawed in a bath at 37 ° C and mixed with 200 ^ 1 of an acid detergent solution (0.08 N HCl, 0.15 M NaCl, 0.15 Triton X 100; pH 1.4) After 30 seconds of exposure to the detergent acid, staining was performed with Acridine orange by adding 1.2 mL of the staining solution containing 6 gd and AO per mL of buffer (0.037 M of citric acid, 0.126 M Na2HPO4, 0.0011 M EDTA (di-sodium), 0.15 M NaCl, pH 6.0). Exactly 3 minutes after staining, the samples were analyzed in a flow cytometer equipped with standard optics and an argon laser tuned at 488 m. The cell flow is
    5
    10
    fifteen
    twenty
    25
    30
    35
    It maintained around 200 cells / s and 5000 events were counted for each sample. The data corresponding to the red (FL3 photodetector; 670 long pass filter) and the green fluorescence (FL1 photodetector; 530/30 band pass filter) of acquired particles were recorded and analyzed with the free Weasel 3.1 software. The main parameter, the DNA fragmentation index (DFI), which corresponds to a relationship between red fluorescence and total fluorescence (red and green) was analyzed.
    The statistical analysis was carried out using the SPSS version 20 program. Data are presented as mean ± SE in all cases. The mean values of each variable were compared using a Student t test for related samples (p <0.05).
    The motility status of the donors was corroborated in the control sampling where it was certified that the volunteers were classified as astenozoospermic following the standards of the World Health Organization (WHO, 2010). The value of motile cells recorded in this sampling was 5.56 ± 2.51% (mean value ± error). After three weeks of administration of probiotics (T1), the percentage of mobile sperm increased about five times compared to the previous sampling, reaching a value of 31.88 ± 6.01% (mean value ± error). This increase was maintained at six weeks of probiotic intake (T2), as well as in the two subsequent sampling performed at 3 and 6 weeks after the end of the administration of probiotics (L1 and L2). The data collected were respectively: 28.14 ± 8.79; 33.25 ± 6.38 and 39.57 ± 8.52% (mean value ± error) (Fig. 1). After performing the statistical analysis, significant differences were found between the control and the other samples (Student's t for related samples, p <0.05). See Figure 1.
    Figure 2 shows the average percentage values obtained at each key point along the experimental design for the DNA fragmentation index. In the control sampling (C) the highest DFI (sperm DNA fragmentation index) was found: 25.74 ± 0.59%. After six weeks of administration of probiotics, the percentage of damaged DNA was reduced to 21.11 ± 1.00 and 21.58 ± 0.94% (T1 and T2 respectively). This trend was maintained in the first wash (L1) whose average was 21.64 ± DFI 1.73%. Six weeks after the end of the exposure to the strains, the improvement seen during the previous sampling began to change in wash 2 (L2) where a higher DFI was registered compared to T1, T2 and L1 with a fragmentation index 23.09 ± 1.28%,
    5
    10
    fifteen
    twenty
    25
    30
    35
    therefore changing the trend. Significant differences (Student's t for related samples, p <0.05) were found with control sampling at T1, T2 and L1.
    The results demonstrate the stimulating role on sperm motility of the Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347 strains when ingested as a functional nutritional composition. A significant reduction in sperm DNA fragmentation after treatment has also been confirmed.
    Example 2. Antioxidant activity of Lactobacillus rhamnosus CECT 8361
    A scrutiny of 23 isolates of the genus Lactobacillus belonging to the collection of one of the two applicants of the present invention, namely Biopolis, S.L., was carried out based on their antioxidant activity in C. elegans. The strains included in the study were isolated from feces of children with exclusive breastfeeding less than 3 months of age.
    Figure 3 shows the results obtained with the Lactobacillus strain of the study. The data represent the percentage of survival increase of the C. elegans animal model fed with each bacterial strain with respect to C. elegans grown under standard conditions (Escherichia coli OP50 strain). As can be seen, isolate 1, identified as Lactobacillus rhamnosus, was the one that provided the greatest survival to C. elegans, after applying an oxidative stress with hydrogen peroxide (a 27% increase in survival compared to control conditions).
    The unequivocal identification of isolate 1 was carried out by sequencing the 16S ribosomal DNA (rDNA) and subsequent comparison of the sequence obtained with the total gene sequences deposited in public databases using the BLAST line tool ( http://blast.ncbi.nlm.nih.gov/Blast.cgi) of the NCBI (National Center for Biotechnology Information). The strain of the present invention CECT 8361 was identified as Lactobacillus rhamnosus obtaining the highest homology (100%) with the public sequences belonging to this species. The strain was deposited in the Spanish Type Culture Collection (CECT) as CECT 8361.
    V01V0111101N0V0110100N00V1100VV0VV00N0NV00VV0011V 02
    VlllOOlOlVOOVNOlOOOOVVOVOOOOOOOOOOOVOllVVOOVVVOlOVVVOl NOOVVOOOOVNOVIOVOOOOIOOOOOIIVOOVVIIVOOOVVIOOVOOOOOIOVO 11000000111000V00110100V1001VV01V00VVV100001V0010V10010 OOVIVOVNNVOOVOVVOOOVIOOOIVOOVVVOOIOONVOIOOOVOIOVVIOIOI OOIOIOIOOOOON VVOOOOIOVOOVOVVOVVOOIVIVIVOVIOOOIVVVOIOOO 91
    OVIOIOIVOOIOVVOOIOVOVOOVOVVOVOOIOVOIIOVVVOOOIOVVVOOOIV OOlOVVOOVOOOVVllOOOOlOOOOVVVOlOlVOlOlOVVllllllOOOOOVOOO OVOOOVVVIOOOOOIIVIIIVOOOOIVIIOOOVVOOOIOOVIOOVIVVIOOOOO OOVOOVOOOIOOVIOVVIOOOOVOOOVVVOVOOVVOOIVIOOOVOIOOOOOIOI 1010VV10V0V00001001VV0VV0V001101101010VVVV1001000011100 01
    OVVOVVOIOVOIOOOOOOOVVOOVOOIVOIOIOVVOOOVOOIVVOVOOIIOIVV 000V10V00V000V0000V10010VVV000000V0V0V010V00011V0V000 OOIVOIIOOVOVOIOVVOOOOVIOOVIVOIVVOOOVVOOVOIOOOOVVIOOVOI OOIIOVIOOVIIVIOOOOOOOOOVOOIVOOIIIIOOOIVIOOVVIOOOOIVOVVV OlOOOllOllOOl VOOOOVVOVVOOIVVVIVOOOOVIVVIOOIVOVOVVVOOIII 9 V0VV1V0000010VV110000100VV1000100V0VV10V010000V0000010 V00VV01111VV111V01101V001100100VVV011V11VN10110V00VV0010
    1988 1030 snsouuieLiJ snn! Oeqope ~ i sp S91 JNQV | 9P uopepuenoes e ep epjuejqo epuenoes - l ON Ql 03S
    S 1.02-90-80 ZZ6l.et7l.02d
    权利要求:
    Claims (19)
    [1]
    5
    10
    fifteen
    twenty
    25
    30
    35
    1. Use of a strain of Lactobacillus rhamnosus in combination with a strain of Bifidobacterium longum in the preparation of a composition to increase male fertility in a subject.
    [2]
    2. Use according to claim 1, wherein the ratio Lactobacillus rhamnosus: Bifidobacterium longum is 50:50.
    [3]
    3. Use according to claim 1 or 2, wherein the composition is a pharmaceutical composition or a functional nutritional composition.
    [4]
    4. Use according to claim 3, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and / or excipient.
    [5]
    5. Use according to claim 3 or 4, wherein the pharmaceutical composition is formulated for oral administration.
    [6]
    6. Use according to claim 3, wherein the functional nutritional composition is a food or nutritional supplement.
    [7]
    7. Use according to claim 6, wherein the food is selected from the group consisting of a dairy product, a meat product, a vegetable product, a fodder and a beverage.
    [8]
    8. Use according to any of claims 1 to 7, wherein the subject is a fish or a mammal, preferably, a mammal selected from the group consisting of a human being, a pig, a horse, a rabbit, an ox and a bull.
    [9]
    9. Use according to any of claims 1 to 8, wherein the dose of administration of microorganisms of the Lactobacillus rhamnosus and Bifidobacterium longum strains in the composition is between 106 and 1012 cfu / day, preferably 109 cfu / day.
    [10]
    10. Use according to claim 9, wherein the administration regime of the composition is at least once a day.
    5
    10
    fifteen
    twenty
    25
    30
    35
    [11]
    11. Use according to any of claims 1 to 10, wherein the Lactobacillus rhamnosus strain is the Lactobacillus rhamnosus CECT 8361 strain and / or the Bifidobacterium longum strain is the Bifidobacterium longum CECT 7347 strain.
    [12]
    12. A composition comprising the Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347 strains or strains derived therefrom, the combination of which presents the ability to increase male fertility.
    [13]
    13. Composition according to claim 12, wherein the ratio Lactobacillus rhamnosus CECT 8361: Bifidobacterium longum CECT 7347 is 50:50.
    [14]
    14. Composition according to claim 12 or 13, wherein the composition is a pharmaceutical composition or a functional nutritional composition.
    [15]
    15. Composition according to claim 14, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and / or excipient.
    [16]
    16. Composition according to claim 14 or 15, wherein the pharmaceutical composition is formulated for oral administration.
    [17]
    17. Composition according to claim 14, wherein the functional nutritional composition is a food or nutritional supplement.
    [18]
    18. Composition according to claim 17, wherein the food is selected from the group consisting of a dairy product, a meat product, a vegetable product, a fodder and a beverage.
    [19]
    19. Composition according to any of claims 12 to 18, wherein the total concentration of microorganisms of the Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347 strains in the composition is between 106 and 1012 cfu, preferably 109 cfu.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP3313423B1|2019-04-24|Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
    ES2720263T3|2019-07-19|Compositions comprising a bacterial strain of Blautia hydrogenotrophica for use in the treatment or prevention of diarrhea or constipation
    ES2540569T3|2015-07-10|Bifidobacteria producing folic acid, food composition and use of said bifidobacteria
    ES2522898T3|2014-11-19|Compositions and methods to treat or prevent an oxalate-related disease
    ES2568955T3|2016-05-05|Metabolically active microorganisms and methods for their production
    ES2575828B1|2017-07-07|Use of probiotics in increasing male fertility
    CN107636146A|2018-01-26|It is engineered to treat the bacterium of the disease for the gastrointestinal mucosal barrier benefited from the alimentary canal inflammation of reduction and/or tightened up
    JP5615285B2|2014-10-29|Composition for preventing or treating anemia
    ES2865269T3|2021-10-15|Lactobacillus salivarius strain, a composition that includes it and uses of it
    ES2856053T3|2021-09-27|Synthetic composition and procedure to promote mucosal healing
    US9131708B2|2015-09-15|Probiotics for dietary dairy product
    Zhang et al.2020|Effects of dietary xylooligosaccharide on growth performance, enzyme activity and immunity of juvenile grass carp, Ctenopharyngodon idellus
    US20220016184A1|2022-01-20|Compositions comprising bacterial strains
    Zeng et al.2015|Oral administration of N-carbamylglutamate might improve growth performance and intestinal function of suckling piglets
    ES2225238T3|2005-03-16|NUTRITIONAL COMPOSITIONS CONTAINING NON-DIGERABLE POLYSACARIDS AND THEIR USE TO REDUCE TRANSPORTATION THROUGH THE NARROW UNIONS.
    ES2760256T3|2020-05-13|Composition
    ES2648055T3|2017-12-28|Strains of probiotic bacteria that produce conjugated linoleic acid and use thereof for the preparation of a pharmaceutical composition
    ES2856673T3|2021-09-28|IgA secretory compositions, manufacturing methods and methods of using them
    ES2683190T3|2018-09-25|Probiotic for excessive childhood crying
    TWI740057B|2021-09-21|An active substance of bifidobacterium lactis gkk2, a composition comprising thereof and its use for promoting longevity
    ES2239341T3|2005-09-16|USE OF A DEHYDRATED PREPARATION CONTAINING PROPIONIC BACTERIA FOR THE PREPARATION OF A SUSTAINABLE ABSORBABLE DIET COMPOSITION OF IMPROVING THE BIOLOGICAL BALANCE OF THE INTESTINAL TRACT FLORA.
    US11224620B2|2022-01-18|Compositions comprising bacterial strains
    Golini2015|The effect of an alkaline buffered creatine |, on cell membrane behavior, protein synthesis, and cisplatin-mediated cellular toxicity
    WO2009084122A1|2009-07-09|Iron-enriched composition
    同族专利:
    公开号 | 公开日
    US20180071347A1|2018-03-15|
    CO2017007338A2|2017-09-29|
    RU2017122615A|2019-01-31|
    KR20170126446A|2017-11-17|
    MX2017008700A|2017-10-27|
    CL2017001706A1|2018-05-11|
    AU2015373326A1|2017-08-17|
    BR112017014217A2|2018-05-29|
    JP2018508473A|2018-03-29|
    RU2724534C2|2020-06-23|
    CN107438438B|2021-08-13|
    EP3241893A1|2017-11-08|
    RU2017122615A3|2019-05-30|
    PE20171770A1|2017-12-21|
    CA2972167A1|2016-07-07|
    US10434127B2|2019-10-08|
    WO2016107948A1|2016-07-07|
    ES2575828B1|2017-07-07|
    AU2015373326B2|2021-11-04|
    CN107438438A|2017-12-05|
    JP6691918B2|2020-05-13|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US6576634B1|2000-07-07|2003-06-10|N.V. Nutricia|Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality|
    US20040156923A1|2002-10-23|2004-08-12|Davenport David F.|Method and nutraceutical composition for mammals|
    GB2418431A|2004-09-27|2006-03-29|Multigerm Uk Entpr Ltd|Metabolically active micro organisms and methods for their production|
    AT503219B1|2006-02-03|2008-07-15|Annerl Brigitte|COMBINATION PREPARATION BASED ON ANTIOXIDANTS TO IMPROVE THE SEED QUALITY|
    US8137952B2|2006-03-17|2012-03-20|Probac Ab|Thermostable lactobacillus strains|
    ES2343499B1|2007-12-24|2011-06-10|Consejo Superior De Investigaciones Cientificas|MICROORGANISMS TO IMPROVE THE STATE OF HEALTH OF INDIVIDUALS WITH DISORDERS RELATED TO THE INTAKE OF GLUTEN.|
    US8853269B2|2010-02-04|2014-10-07|Copperhead Chemical Company Inc.|Composition and method for treating infections and promoting intestinal health|EP3222282A1|2016-03-21|2017-09-27|Bionou Research, S.L.|Use of probiotics in the treatment and/or prevention of psoriasis|
    EP3851115A1|2020-01-15|2021-07-21|Biopolis, S.L.|Probiotic composition for its use as an antioxidant|
    CN112442463A|2020-11-25|2021-03-05|北京科拓恒通生物技术股份有限公司|Application of lactobacillus rhamnosus Probio-M9 and preparation thereof in preparing life-prolonging product|
    法律状态:
    2017-07-07| FG2A| Definitive protection|Ref document number: 2575828 Country of ref document: ES Kind code of ref document: B1 Effective date: 20170707 |
    2022-02-28| PC2A| Transfer of patent|Owner name: BIOPOLIS, S.L. Effective date: 20220222 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201431977A|ES2575828B1|2014-12-31|2014-12-31|Use of probiotics in increasing male fertility|ES201431977A| ES2575828B1|2014-12-31|2014-12-31|Use of probiotics in increasing male fertility|
    EP15832801.3A| EP3241893A1|2014-12-31|2015-12-23|Use of probiotics to increase male fertility|
    KR1020177021423A| KR20170126446A|2014-12-31|2015-12-23|Use of probiotics to increase fertility in males|
    MX2017008700A| MX2017008700A|2014-12-31|2015-12-23|Use of probiotics to increase male fertility.|
    PCT/ES2015/070948| WO2016107948A1|2014-12-31|2015-12-23|Use of probiotics to increase male fertility|
    CN201580075578.6A| CN107438438B|2014-12-31|2015-12-23|Use of probiotics for improving male fertility|
    AU2015373326A| AU2015373326B2|2014-12-31|2015-12-23|Use of probiotics to increase male fertility|
    US15/539,542| US10434127B2|2014-12-31|2015-12-23|Use of probiotics to increase male fertility|
    PE2017001164A| PE20171770A1|2014-12-31|2015-12-23|USE OF PROBIOTICS IN THE INCREASE OF MALE FERTILITY|
    CA2972167A| CA2972167A1|2014-12-31|2015-12-23|Use of probiotics to increase male fertility|
    BR112017014217-1A| BR112017014217A2|2014-12-31|2015-12-23|use of probiotics to increase male fertility|
    RU2017122615A| RU2724534C2|2014-12-31|2015-12-23|Using probiotics to enhance male fertility|
    JP2017535798A| JP6691918B2|2014-12-31|2015-12-23|Use of probiotics to improve male fertility|
    CL2017001706A| CL2017001706A1|2014-12-31|2017-06-27|Use of probiotics in increasing male fertility.|
    CONC2017/0007338A| CO2017007338A2|2014-12-31|2017-07-24|Composition comprising two strains of the microbial species lactobacillus rhamnosus and bifidobacterium longum capable of increasing male fertility|
    [返回顶部]